Handok signed an exclusive supply and distribution contract for the cerebral vasospasm prevention drug “PIVLAZ” with Nxera Pharma Korea

Handok has been jointly conducting domestic clinical trials and product licensing work for PIVLAZ with Nxera Pharma Korea since 2008. PIVLAZ was granted product approval by the Ministry of Food and Drug Safety on December 7, 2023, and with this contract, Handok will be responsible for the domestic marketing, sales, and distribution of PIVLAZ.

PIVLAZ (ingredient: Clazosentan) is a selective endothelin A receptor antagonist indicated for the prevention of cerebral vasospasm and related cerebral infarction and ischemic symptoms in adults who have undergone craniotomy (clipping) or endovascular treatment (coiling) for aneurysmal subarachnoid hemorrhage. It is the first drug in the country approved for preventing both cerebral vasospasm and its complications.

Despite the seriousness of cerebral vasospasm following aneurysmal subarachnoid hemorrhage, which can lead to death, there has been a significant challenge in the medical field due to the absence of drugs. At least 25% of patients with aneurysmal subarachnoid hemorrhage die, and about 50% of survivors have neurological deficits. In particular, cerebral vasospasm following aneurysmal subarachnoid hemorrhage doubles the risk of death in treated patients and can lead to serious complications such as local paralysis, speech disorders, and decreased consciousness, making active prevention and treatment crucial. Cerebral vasospasm is more likely to occur in patients over 65, but it tends to be more severe in younger patients.